About To Get Real !!!
Updated:
ELTP Catalyst
X 1. Cash Flow Positive - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million IMS market Approved and Launched
X 4. Adderall XR $1.56 Billion IMS market Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement - January 1st 2024
X 8. First shipment Adderall XR to Prasco Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
X 12. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__13. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 14. Vigabatrin Approval $233 Million
X 15. Pyros Vigabatrin -settle VigPoder trade mark challenge then LAUNCH
X 16. Generic Methotrexate Approval- Antimetabolite $42 Million
__17. $50+ million in yearly revenues
X 18. Lowest PE ratio for OTC Healthcare sector
X 19. Become the ONLY company showing rapid growth on the OTC while being profitable
__20. Generate revenues over $20 million/quarter
__21. Double output of manufacturing and packaging facilities
__22. Generic OxyContin Approval - FIRST TO FILE Aug 17, 2023 $720 Million
__23. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__24. Launch Tylenol with codeine $45 Million
__25. Launch generic Norco - hydrocodone acetaminophen IMS $477 Million
__26. Launch generic Percocet - oxycodone acetaminophen IMS $500 Million
__27. Launch generic Dolophine - methadone HCL tablets IMS $30 Million
__28. European distribution - Dexcel partnership approval by Israeli Health
__29. Full ownership of Adderall IR $ 335 Million
__30. Full ownership of Adderall XR $ 1.56 Billion
__31. Generic Concerta- $1.2 BILLION FDA submission
__32. $100 million in yearly revenue
__33. Generic Vyvanse Approval and Launch
__34. $200 million in yearly revenue
__35. Deep pocket partner for SequestOx
__36. Patented Unique ADF (w/o naltrexone) drug C in SequestOx trial
__37. Mikah ANDA(s)
__38. Undisclosed ANDAs/NDAs
__39. Generic Concerta Approval and Launch
__40. DollarLand PPS
__41. Big Pharma bid
__42. UpList to the NASDAQ Exchange
__43. ELTP Elite Pharmaceutical Buyout - 2 1/2 years or less from Feb 2024
__44. Vegas Baby !!!!!!!
ELTP
Bullish
